STARPHARMA HOLDINGS LIMITED - Announcements

0.00%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

SPL	Enrolment complete for Phase 3 VivaGel BV-R program-SPL.AX	PRICE SENSITIVE	13/10/16	102.91KB	Share
SPL	VivaGel condom receives regulatory approval in Canada-SPL.AX	PRICE SENSITIVE	13/09/16	924.91KB	Share
SPL	Annual report and full year financial results-SPL.AX	PRICE SENSITIVE	29/08/16	2.79MB	Share
SPL	New DEP drug delivery program initiated with AstraZeneca-SPL.AX	PRICE SENSITIVE	28/07/16	81.78KB	Share
SPL	Starpharma signs license for a VivaGel condom in China-SPL.AX	PRICE SENSITIVE	21/07/16	118.11KB	Share
SPL	Appendix 4C - Quarterly Cashflow Reoprt-SPL.AX	PRICE SENSITIVE	14/07/16	115.75KB	Share
SPL	Starpharma's DEP eliminates cabazitaxel neutropenia-SPL.AX	PRICE SENSITIVE	25/05/16	168.89KB	Share
SPL	VivaGel active against Zika virus-SPL.AX	PRICE SENSITIVE	05/05/16	97.19KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report-SPL.AX	PRICE SENSITIVE	28/04/16	210.3KB	Share
SPL	DEP cabazitaxel shows complete, sustained tumour regression-SPL.AX	PRICE SENSITIVE	04/04/16	173.5KB	Share
SPL	Adama Licenses Starpharma's Priostar for Novel 2,4-D	PRICE SENSITIVE	17/03/16	113.63KB	Share
SPL	Starpharma licences VivaGel BV to Aspen for ANZ	PRICE SENSITIVE	04/03/16	171.35KB	Share
SPL	Interim Report and Half-Year Financial Results	PRICE SENSITIVE	17/02/16	608.58KB	Share
SPL	Targeted DEP shows sustained superior performance	PRICE SENSITIVE	02/02/16	263.74KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	28/01/16	159.74KB	Share
SPL	Starpharma raises $1.9M under Share Purchase Plan	PRICE SENSITIVE	20/01/16	91.88KB	Share
SPL	Starpharma signs MOU for VivaGel condom in China	PRICE SENSITIVE	16/12/15	220.91KB	Share
SPL	Starpharma completes A$32 million placement	PRICE SENSITIVE	09/12/15	88.92KB	Share
SPL	Trading Halt	PRICE SENSITIVE	07/12/15	285.04KB	Share
SPL	DEP outperforms leading treatments in ovarian cancer model	PRICE SENSITIVE	16/11/15	302.61KB	Share
SPL	Starpharma receives $3.4M R&D tax incentive	PRICE SENSITIVE	12/11/15	124.55KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/10/15	136.6KB	Share
SPL	Additional US Patent Granted for VivaGel BV	PRICE SENSITIVE	14/10/15	122.21KB	Share
SPL	EU Marketing Approval Granted for VivaGel BV	PRICE SENSITIVE	24/09/15	124.11KB	Share
SPL	Starpharma signs drug delivery license with AstraZeneca	PRICE SENSITIVE	07/09/15	142.54KB	Share
SPL	Annual report and full year financial results	PRICE SENSITIVE	21/08/15	2.5MB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/07/15	131.89KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/04/15	158.2KB	Share
SPL	DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level	PRICE SENSITIVE	30/04/15	361.15KB	Share
SPL	Interim Report and Half-Year Financial Results	PRICE SENSITIVE	16/02/15	416.1KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	28/01/15	322.29KB	Share
SPL	Japan VivaGel condom classification impacts launch timing	PRICE SENSITIVE	05/12/14	388.32KB	Share
SPL +ANN EBO	Marketing Clearance for VivaGel condom in New Zealand	PRICE SENSITIVE	28/11/14	110.33KB	Share
SPL	Response to ASX Price Query	PRICE SENSITIVE	17/11/14	104.56KB	Share
SPL	Starpharmas Priostar Glyphosate Patent Allowed in China	PRICE SENSITIVE	13/11/14	97.26KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/14	119.31KB	Share
SPL	Starpharma receives $4.2M R&D tax incentive refund	PRICE SENSITIVE	29/10/14	96.34KB	Share
SPL	DEP docetaxel - longer duration and increased exposure	PRICE SENSITIVE	20/10/14	114.28KB	Share
SPL +ANN	VivaGel condom approved for sale with launch imminent	PRICE SENSITIVE	02/10/14	114.51KB	Share
SPL	SPP Record Date Clarification	PRICE SENSITIVE	22/09/14	90.53KB	Share
SPL	Starpharma completes A$18 million placement, SPP to follow	PRICE SENSITIVE	22/09/14	98.94KB	Share
SPL	Trading Halt	PRICE SENSITIVE	18/09/14	265.77KB	Share
SPL	Annual report and full year financial results	PRICE SENSITIVE	13/08/14	4.21MB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	31/07/14	147.28KB	Share
SPL	VivaGel condom receives TGA device certification	PRICE SENSITIVE	21/07/14	108.69KB	Share
SPL	FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial	PRICE SENSITIVE	14/07/14	95.26KB	Share
SPL	Starpharma clinical trial programs accelerating	PRICE SENSITIVE	05/06/14	114.57KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/04/14	110.39KB	Share
SPL	Starpharma expands Drug Delivery Program with AstraZeneca	PRICE SENSITIVE	07/04/14	104.72KB	Share
SPL	VivaGel-coated condom approved for marketing in Japan	PRICE SENSITIVE	14/03/14	189.96KB	Share
SPL	Starpharma Interim Report and Half-year Financial Results	PRICE SENSITIVE	24/02/14	706.53KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/01/14	316.05KB	Share
SPL	Response to ASX Price Query	PRICE SENSITIVE	23/01/14	1.79MB	Share
SPL	Starpharma commences Dendrimer-Docetaxel clinical trial	PRICE SENSITIVE	23/01/14	364.44KB	Share
SPL	Starpharma to recoup additional $2 million for overseas R&D	PRICE SENSITIVE	14/01/14	95.02KB	Share
SPL	Cancer Australia funding for dendrimer-based lung treatment	PRICE SENSITIVE	19/12/13	453.46KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/13	142.3KB	Share
SPL	Starpharma Dendrimer-Docetaxel eliminates neutropenia	PRICE SENSITIVE	24/10/13	152.32KB	Share
SPL	Reduced neurotoxicity - SPL's dendrimer enhanced oxaliplatin	PRICE SENSITIVE	14/10/13	218.48KB	Share
SPL	SPL Signs Priostar Agrochemical Partnership with Gowan	PRICE SENSITIVE	16/09/13	84.01KB	Share
SPL	Dendrimer-Oxaliplatin shows better anti-cancer efficacy	PRICE SENSITIVE	11/09/13	270.16KB	Share
SPL	Annual report and full year financial results	PRICE SENSITIVE	26/08/13	1.8MB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	25/07/13	141.88KB	Share
SPL	ARC grant for Starpharma's targeted drug delivery	PRICE SENSITIVE	11/07/13	111.8KB	Share
SPL	SPL's dendrimer a potential viral conjunctivitis treatment	PRICE SENSITIVE	13/05/13	67.83KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/13	139.97KB	Share
SPL	Starpharma Granted New Drug Delivery Patents	PRICE SENSITIVE	17/04/13	150.5KB	Share
SPL	Dendrimers improve anticancer efficacy lung metastasis model	PRICE SENSITIVE	04/03/13	215.35KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	14/02/13	1.77MB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/13	109.65KB	Share
SPL	SPL docetaxel superior to Taxotere across multiple cancers	PRICE SENSITIVE	06/12/12	162.93KB	Share
SPL	VivaGel phase 3 study results	PRICE SENSITIVE	28/11/12	158.2KB	Share
SPL	Trading Halt	PRICE SENSITIVE	28/11/12	114.97KB	Share
SPL	Starpharma to recoup $6 million cash for overseas R&D	PRICE SENSITIVE	22/11/12	95.79KB	Share
SPL	Starpharma presenting at Bell Potter LifeScience Conference	PRICE SENSITIVE	01/11/12	2.39MB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/12	236.44KB	Share
SPL	New formulations show further improvement in crop protection	PRICE SENSITIVE	30/10/12	269.94KB	Share
SPL	Starpharma's docetaxel demonstrates targeted tumour delivery	PRICE SENSITIVE	29/10/12	365.51KB	Share
SPL	VivaGel BV Phase 3 trials - recruitment complete	PRICE SENSITIVE	18/10/12	125.47KB	Share
SPL	Starpharma signs cancer drug agreement with AstraZeneca	PRICE SENSITIVE	06/09/12	114.8KB	Share
SPL	Annual Report and full year financial results	PRICE SENSITIVE	27/08/12	1.71MB	Share
NUF +SPL	Starpharma and Nufarm sign crop protection agreement	PRICE SENSITIVE	07/08/12	108.69KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/12	213.33KB	Share
SPL	Reports rapid advancement of drug delivery program	PRICE SENSITIVE	03/07/12	152.19KB	Share
SPL	Full enrolment achieved for BV Phase 2 & first Phase 3 trial	PRICE SENSITIVE	25/06/12	161.92KB	Share
SPL	Starpharma's VivaGel Phase 3 trials 60% enrolled	PRICE SENSITIVE	04/06/12	130.7KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	154.88KB	Share
SPL	Response to an ASX price query	PRICE SENSITIVE	24/04/12	136.48KB	Share
SPL	SPL Commences pivotal phase 3 VivaGel BV treatment trials	PRICE SENSITIVE	22/03/12	193.59KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	20/02/12	639.37KB	Share
SPL	SPL's dendrimers improve efficacy of docetaxel in animals	PRICE SENSITIVE	01/02/12	189.28KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/12	123.68KB	Share
SPL	SPL receives FDA Special Protocol Assessment for BV Phase 3	PRICE SENSITIVE	11/01/12	78KB	Share
SPL	Starpharma's drug delivery program with Lilly advances	PRICE SENSITIVE	19/12/11	101.24KB	Share
SPL	Starpharma secures European (EMA) agreement on BV Phase 3	PRICE SENSITIVE	21/11/11	103.06KB	Share
SPL	Starpharma completes A$32 million placement, SPP to follow	PRICE SENSITIVE	16/11/11	125.11KB	Share
SPL	Trading Halt	PRICE SENSITIVE	14/11/11	52.38KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/11	165.23KB	Share
SPL	Starpharma secures FDA agreement on BV treatment Phase 3	PRICE SENSITIVE	10/10/11	150.94KB	Share
ACR +ALD ALK API ASZ BKY BSL CCP CNP CPB ATT DCG K2P FML ETM GMG HIL HUN IDL IFN ILU MCP MCR MEO MTU NDO OST PPT SRS IMM QUB RHG SFH SPL SSN STB TGA TGS ZSP	SandP Indices Announces September Quarterly Rebalance	PRICE SENSITIVE	09/09/11	62.33KB	Share

SPL Enrolment complete for Phase 3 VivaGel BV-R program-SPL.AX
13/10/16	PRICE SENSITIVE	102.91KB	Share
SPL VivaGel condom receives regulatory approval in Canada-SPL.AX
13/09/16	PRICE SENSITIVE	924.91KB	Share
SPL Annual report and full year financial results-SPL.AX
29/08/16	PRICE SENSITIVE	2.79MB	Share
SPL New DEP drug delivery program initiated with AstraZeneca-SPL.AX
28/07/16	PRICE SENSITIVE	81.78KB	Share
SPL Starpharma signs license for a VivaGel condom in China-SPL.AX
21/07/16	PRICE SENSITIVE	118.11KB	Share
SPL Appendix 4C - Quarterly Cashflow Reoprt-SPL.AX
14/07/16	PRICE SENSITIVE	115.75KB	Share
SPL Starpharma's DEP eliminates cabazitaxel neutropenia-SPL.AX
25/05/16	PRICE SENSITIVE	168.89KB	Share
SPL VivaGel active against Zika virus-SPL.AX
05/05/16	PRICE SENSITIVE	97.19KB	Share
SPL Appendix 4C - Quarterly Cashflow Report-SPL.AX
28/04/16	PRICE SENSITIVE	210.3KB	Share
SPL DEP cabazitaxel shows complete, sustained tumour regression-SPL.AX
04/04/16	PRICE SENSITIVE	173.5KB	Share
SPL Adama Licenses Starpharma's Priostar for Novel 2,4-D
17/03/16	PRICE SENSITIVE	113.63KB	Share
SPL Starpharma licences VivaGel BV to Aspen for ANZ
04/03/16	PRICE SENSITIVE	171.35KB	Share
SPL Interim Report and Half-Year Financial Results
17/02/16	PRICE SENSITIVE	608.58KB	Share
SPL Targeted DEP shows sustained superior performance
02/02/16	PRICE SENSITIVE	263.74KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
28/01/16	PRICE SENSITIVE	159.74KB	Share
SPL Starpharma raises $1.9M under Share Purchase Plan
20/01/16	PRICE SENSITIVE	91.88KB	Share
SPL Starpharma signs MOU for VivaGel condom in China
16/12/15	PRICE SENSITIVE	220.91KB	Share
SPL Starpharma completes A$32 million placement
09/12/15	PRICE SENSITIVE	88.92KB	Share
SPL Trading Halt
07/12/15	PRICE SENSITIVE	285.04KB	Share
SPL DEP outperforms leading treatments in ovarian cancer model
16/11/15	PRICE SENSITIVE	302.61KB	Share
SPL Starpharma receives $3.4M R&D tax incentive
12/11/15	PRICE SENSITIVE	124.55KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
30/10/15	PRICE SENSITIVE	136.6KB	Share
SPL Additional US Patent Granted for VivaGel BV
14/10/15	PRICE SENSITIVE	122.21KB	Share
SPL EU Marketing Approval Granted for VivaGel BV
24/09/15	PRICE SENSITIVE	124.11KB	Share
SPL Starpharma signs drug delivery license with AstraZeneca
07/09/15	PRICE SENSITIVE	142.54KB	Share
SPL Annual report and full year financial results
21/08/15	PRICE SENSITIVE	2.5MB	Share
SPL Appendix 4C - Quarterly Cashflow Report
30/07/15	PRICE SENSITIVE	131.89KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
30/04/15	PRICE SENSITIVE	158.2KB	Share
SPL DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level
30/04/15	PRICE SENSITIVE	361.15KB	Share
SPL Interim Report and Half-Year Financial Results
16/02/15	PRICE SENSITIVE	416.1KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
28/01/15	PRICE SENSITIVE	322.29KB	Share
SPL Japan VivaGel condom classification impacts launch timing
05/12/14	PRICE SENSITIVE	388.32KB	Share
SPL +ANN EBO Marketing Clearance for VivaGel condom in New Zealand
28/11/14	PRICE SENSITIVE	110.33KB	Share
SPL Response to ASX Price Query
17/11/14	PRICE SENSITIVE	104.56KB	Share
SPL Starpharmas Priostar Glyphosate Patent Allowed in China
13/11/14	PRICE SENSITIVE	97.26KB	Share
SPL Appendix 4C - quarterly
31/10/14	PRICE SENSITIVE	119.31KB	Share
SPL Starpharma receives $4.2M R&D tax incentive refund
29/10/14	PRICE SENSITIVE	96.34KB	Share
SPL DEP docetaxel - longer duration and increased exposure
20/10/14	PRICE SENSITIVE	114.28KB	Share
SPL +ANN VivaGel condom approved for sale with launch imminent
02/10/14	PRICE SENSITIVE	114.51KB	Share
SPL SPP Record Date Clarification
22/09/14	PRICE SENSITIVE	90.53KB	Share
SPL Starpharma completes A$18 million placement, SPP to follow
22/09/14	PRICE SENSITIVE	98.94KB	Share
SPL Trading Halt
18/09/14	PRICE SENSITIVE	265.77KB	Share
SPL Annual report and full year financial results
13/08/14	PRICE SENSITIVE	4.21MB	Share
SPL Appendix 4C - Quarterly Cashflow Report
31/07/14	PRICE SENSITIVE	147.28KB	Share
SPL VivaGel condom receives TGA device certification
21/07/14	PRICE SENSITIVE	108.69KB	Share
SPL FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
14/07/14	PRICE SENSITIVE	95.26KB	Share
SPLStarpharma clinical trial programs accelerating
05/06/14	PRICE SENSITIVE	114.57KB	Share
SPLAppendix 4C - Quarterly Cashflow Report
30/04/14	PRICE SENSITIVE	110.39KB	Share
SPLStarpharma expands Drug Delivery Program with AstraZeneca
07/04/14	PRICE SENSITIVE	104.72KB	Share
SPLVivaGel-coated condom approved for marketing in Japan
14/03/14	PRICE SENSITIVE	189.96KB	Share
SPLStarpharma Interim Report and Half-year Financial Results
24/02/14	PRICE SENSITIVE	706.53KB	Share
SPLAppendix 4C - Quarterly Cashflow Report
30/01/14	PRICE SENSITIVE	316.05KB	Share
SPLResponse to ASX Price Query
23/01/14	PRICE SENSITIVE	1.79MB	Share
SPLStarpharma commences Dendrimer-Docetaxel clinical trial
23/01/14	PRICE SENSITIVE	364.44KB	Share
SPLStarpharma to recoup additional $2 million for overseas R&D
14/01/14	PRICE SENSITIVE	95.02KB	Share
SPLCancer Australia funding for dendrimer-based lung treatment
19/12/13	PRICE SENSITIVE	453.46KB	Share
SPLAppendix 4C - quarterly
28/10/13	PRICE SENSITIVE	142.3KB	Share
SPLStarpharma Dendrimer-Docetaxel eliminates neutropenia
24/10/13	PRICE SENSITIVE	152.32KB	Share
SPLReduced neurotoxicity - SPL's dendrimer enhanced oxaliplatin
14/10/13	PRICE SENSITIVE	218.48KB	Share
SPLSPL Signs Priostar Agrochemical Partnership with Gowan
16/09/13	PRICE SENSITIVE	84.01KB	Share
SPLDendrimer-Oxaliplatin shows better anti-cancer efficacy
11/09/13	PRICE SENSITIVE	270.16KB	Share
SPLAnnual report and full year financial results
26/08/13	PRICE SENSITIVE	1.8MB	Share
SPLAppendix 4C - quarterly
25/07/13	PRICE SENSITIVE	141.88KB	Share
SPLARC grant for Starpharma's targeted drug delivery
11/07/13	PRICE SENSITIVE	111.8KB	Share
SPLSPL's dendrimer a potential viral conjunctivitis treatment
13/05/13	PRICE SENSITIVE	67.83KB	Share
SPLAppendix 4C - quarterly
24/04/13	PRICE SENSITIVE	139.97KB	Share
SPLStarpharma Granted New Drug Delivery Patents
17/04/13	PRICE SENSITIVE	150.5KB	Share
SPLDendrimers improve anticancer efficacy lung metastasis model
04/03/13	PRICE SENSITIVE	215.35KB	Share
SPLHalf Yearly Report and Accounts
14/02/13	PRICE SENSITIVE	1.77MB	Share
SPLAppendix 4C - quarterly
30/01/13	PRICE SENSITIVE	109.65KB	Share
SPLSPL docetaxel superior to Taxotere across multiple cancers
06/12/12	PRICE SENSITIVE	162.93KB	Share
SPLVivaGel phase 3 study results
28/11/12	PRICE SENSITIVE	158.2KB	Share
SPLTrading Halt
28/11/12	PRICE SENSITIVE	114.97KB	Share
SPLStarpharma to recoup $6 million cash for overseas R&D
22/11/12	PRICE SENSITIVE	95.79KB	Share
SPLStarpharma presenting at Bell Potter LifeScience Conference
01/11/12	PRICE SENSITIVE	2.39MB	Share
SPLAppendix 4C - quarterly
31/10/12	PRICE SENSITIVE	236.44KB	Share
SPLNew formulations show further improvement in crop protection
30/10/12	PRICE SENSITIVE	269.94KB	Share
SPLStarpharma's docetaxel demonstrates targeted tumour delivery
29/10/12	PRICE SENSITIVE	365.51KB	Share
SPLVivaGel BV Phase 3 trials - recruitment complete
18/10/12	PRICE SENSITIVE	125.47KB	Share
SPLStarpharma signs cancer drug agreement with AstraZeneca
06/09/12	PRICE SENSITIVE	114.8KB	Share
SPLAnnual Report and full year financial results
27/08/12	PRICE SENSITIVE	1.71MB	Share
NUF +SPLStarpharma and Nufarm sign crop protection agreement
07/08/12	PRICE SENSITIVE	108.69KB	Share
SPLAppendix 4C - quarterly
30/07/12	PRICE SENSITIVE	213.33KB	Share
SPLReports rapid advancement of drug delivery program
03/07/12	PRICE SENSITIVE	152.19KB	Share
SPLFull enrolment achieved for BV Phase 2 & first Phase 3 trial
25/06/12	PRICE SENSITIVE	161.92KB	Share
SPLStarpharma's VivaGel Phase 3 trials 60% enrolled
04/06/12	PRICE SENSITIVE	130.7KB	Share
SPLAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	154.88KB	Share
SPLResponse to an ASX price query
24/04/12	PRICE SENSITIVE	136.48KB	Share
SPLSPL Commences pivotal phase 3 VivaGel BV treatment trials
22/03/12	PRICE SENSITIVE	193.59KB	Share
SPLHalf Yearly Report and Accounts
20/02/12	PRICE SENSITIVE	639.37KB	Share
SPLSPL's dendrimers improve efficacy of docetaxel in animals
01/02/12	PRICE SENSITIVE	189.28KB	Share
SPLAppendix 4C - quarterly
30/01/12	PRICE SENSITIVE	123.68KB	Share
SPLSPL receives FDA Special Protocol Assessment for BV Phase 3
11/01/12	PRICE SENSITIVE	78KB	Share
SPLStarpharma's drug delivery program with Lilly advances
19/12/11	PRICE SENSITIVE	101.24KB	Share
SPLStarpharma secures European (EMA) agreement on BV Phase 3
21/11/11	PRICE SENSITIVE	103.06KB	Share
SPLStarpharma completes A$32 million placement, SPP to follow
16/11/11	PRICE SENSITIVE	125.11KB	Share
SPLTrading Halt
14/11/11	PRICE SENSITIVE	52.38KB	Share
SPLAppendix 4C - quarterly
27/10/11	PRICE SENSITIVE	165.23KB	Share
SPLStarpharma secures FDA agreement on BV treatment Phase 3
10/10/11	PRICE SENSITIVE	150.94KB	Share
ACR +ALD ALK API ASZ BKY BSL CCP CNP CPB ATT DCG K2P FML ETM GMG HIL HUN IDL IFN ILU MCP MCR MEO MTU NDO OST PPT SRS IMM QUB RHG SFH SPL SSN STB TGA TGS ZSPSandP Indices Announces September Quarterly Rebalance
09/09/11	PRICE SENSITIVE	62.33KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
13.5¢	13.5¢	13.0¢	$30.60K	232.5K

Buyers (Bids)

No.	Vol.	Price($)
1	458760	13.0¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	87374	5

View Market Depth

No.	Vol.	Price($)
1	458760	0.130
2	51308	0.125
1	43350	0.115
2	9099	0.110
2	86433	0.105

Price($)	Vol.	No.
0.135	87374	5
0.140	162743	4
0.145	71840	7
0.150	175000	3
0.155	108518	3

Last trade - 15.09pm 05/09/2025 (20 minute delay)

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Clean energy vehicles with hydrogen production and distribution all under one roof

Prospect Resources continues to advance Mumbezhi project

Leeuwin Metals set to unlock significant gold potential at Marda

Haranga Resources: From uranium in Senegal to gold in the US

Top Stories